InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2024-08-05 00:00:00 ET · period of report 2024-08-01 · accession 0001883850-24-000040 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-08-05 2024-08-01 REGN McCourt Marion EVP Commercial M - OptEx $372.46 +1,137 14.1K +9% +$423.5K
D 2024-08-05 2024-08-01 REGN McCourt Marion EVP Commercial S - Sale+OE $1,060.86 -1,137 12.9K -8% -$1.21M
D 2024-08-05 2024-08-01 REGN McCourt Marion EVP Commercial M - OptEx $0.00 -1,137 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-08-01 M A 1,137 $372.46 14,068 D — —
2 Common Common Stock 2024-08-01 S D 1,137 $1,060.86 12,931 D — —
3 Derivative Non-Qualified Stock Option (right to buy) 2024-08-01 M D 1,137 $0.00 0 D $372.46 · — to 2029-12-11 1,137 Common Stock (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant.